ResMed Stock: Analyst Estimates & Ratings

With a market cap of $33.5 billion, ResMed Inc. (RMD) is a international health technology company that develops modern options to help people dwell more healthy, happier lives through higher sleep and respiration. Operating across 140 nations, the company combines AI-powered digital health options, cloud-connected gadgets, and clever software program to make home healthcare more personalised, accessible, and efficient.

Shares of the San Diego, California-based company have underperformed the broader market over the previous 52 weeks. RMD stock has decreased 18.7% over this time body, while the broader S&P 500 Index ($SPX) has gained 19.3%. Moreover, the stock has fallen 3.6% on a YTD foundation, in contrast to SPX’s 12.2% return.

More News from Barchart

Looking nearer, shares of the medical merchandise maker have also lagged behind the State Street Health Care Select Sector SPDR ETF’s (XLV) 28.1% increase over the previous 52 weeks.

ResMed shares tumbled 5.1% following its This fall 2026 outcomes on Aug. 6 as its fiscal 2027 income steering of $5.75 billion – $5.85 billion was below the analyst expectation, with the outlook assuming no Astral ventilator gross sales and a $75 million income influence from the suspension. The Astral suspension adopted a machine correction and FDA recall linked to 5 severe accidents, while ResMed has not determined whether gross sales will resume in fiscal 2028 and is redirecting scarce digital parts to repairs and servicing, including to investor considerations over growth and provide constraints. 

Despite This fall adjusted EPS of $2.95 beating the estimate and income rising 9% to $1.46 billion, rising electronic-component and freight prices, deliberate price will increase, and competitors further pressured the fiscal 2027 growth outlook.

For the fiscal 12 months ending in June 2027, analysts expect ResMed’s adjusted EPS to grow 7.7% year-over-year to $12.03. The company’s earnings shock historical past is promising. It topped the consensus estimates in each of the last 4 quarters.

Among the 21 analysts protecting the stock, the consensus score is a “Moderate Buy.” That’s primarily based on eight “Strong Buy” scores, 12 “Holds,” and one “Strong Sell.”

This configuration is barely less bullish than three months in the past, with 9 “Strong Buy” scores on the stock.

On Aug. 7, Wells Fargo analyst Nathan Treybeck cut ResMed’s price goal to $215 while sustaining an “Equal Weight” score.

The imply price goal of $238.27 represents a 1.4% premium to RMD’s present price ranges. The Street-high price goal of $320 suggests a 36.3% potential upside. 

On the date of publication, Sohini Mondal did not have (either immediately or not directly) positions in any of the securities talked about in this article. All data and information in this article is solely for informational functions. This article was initially revealed on Barchart.com